out high priced imports for the purpose of regulating imported bulk drug prices and fixing the prices of formulations?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) As already stated in reply to Unstarred Question No. 3086 on 6.8.1992, attention of the drug companies has been invited, through industry associations, to para 6.7 of the Measures for Rationalisation, Quality Control and Growth of Pharmaceutical Industry in India' announced by the Government in December, 1986 requesting them to furnish these details.

However, the response of the industry has not been very encouraging.

(d) Industrial approvals for manufacture of bulk drugs are given only as per basic stages. Manufacture from late stage intermediates is permitted only in a few cases by giving relaxation to the basic stage, taking into consideration various reasons like technological constraints, economic viability etc. Moreover, in order to discourage over-dependence on use of imported bulk drugs, Goverment has stipulated in the Drug Policy a ratio parameter for the use of indigenous and imported bulk drugs in the formulation activity of a drug company in the organised sector.

(e) While fixing the prices of formulations based on imported bulk drugs, weighted average landed price of the bulk drug is taken into consideration.

Import of Ceftazidine bulk drug

3599. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that import of Ceftazidine bulk drug in 1991-92 was more than Rs. 2 crores at CIF cost;

(b) what are the details of quantity imported and its CIF value during each of the years 1991-92 and 1992-93 so far;

(c) whether it is a fact that formulation is being sold by a single company;

(d) if so, name of the company and what was the turnover of the formulation during the past two years year-wise;

(e) what is the price at which the product is being sold;

(f) whether it is a fact that the product is outside the price control;

(g) whether it is a fact that the product falls under monopoly and having turnover of more than five crores per annum; and

(h) if so, the criteria under which such product has been kept outside price control?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) No, Sir.

(b) Total quantity of Ceftazedine bulk drug imported during 1991-92 and 1992-93 so far is 53.9 Kg. and 940.89kg respectively. The c.i.f. value for the two years is Rs. 25.47 lakh and Rs. 756.8 lakh respectively.

(c) Yes, Sir.

(d) M/s. Glaxo India Limited are marketing this formulation. The turnover of the formulations, as per Form-6, was Rs. 7.47 crores and Rs. 9.51 crores during 1990-91 and 1991-92 respectively.

(e) The present price of the formulation is given below:—

Fortum 250 ml vial	— Rs. 106.19
Fortum 500 ml vial	— Rs. 182.61
Fortum 1 gm vial	— Rs. 334.37

(f) Yes, Sir.

(g) and (h) Review of Drug Policy 1986 which includes the evolution of suitable criteria for selecting drugs for the purpose of price control, is in its final stages and a background note has already been placed on the Table of both the Houses of Parliament on 12.8.1992 for discussion.